Algernon Pharmaceuticals Provides Year End Summary of Key Activities
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year. NP-120 Idiopathic Pulmonary Fibrosis & Chronic Cough Clinical Research Program March 30 – Submitted for ethics approval in Australia for a Phase 2 study of the Company’s re-purposed drug Ifenprodil for IPF and chronic cough. May 6 – …
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year.
Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19 globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No securities regulatory authority or stock exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to the closing of the Offering, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other th
Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data
VANCOUVER, British Columbia, Dec. 17, 2020 Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “
Company” or “
Algernon”) a clinical stage pharmaceutical development company, is pleased to provide additional information on its interim data report for the Phase 2b part of the Company’s Phase 2b/3 clinical study of Ifenprodil for COVID-19.
Phase 2b/3 Trial Endpoints
The Algernon Phase 2b/3 COVID-19 clinical trial protocol design was based on WHO guidelines (master protocol version 2.0, February 24, 2020). This design allows for a secondary endpoint to be used as the primary endpoint going forward in the Phase 3 part of the trial.
News Category Global Banking & Finance Reviews
Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
VANCOUVER, British Columbia, Dec. 16, 2020 Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company’s interim data report for the Company’s Phase 2b/3 clinical study of Ifenprodil for COVID-19 on an upcoming